- Home
- ZTR vs TRDA Comparison
ZTR vs TRDA Comparison
Compare ZTR & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- TRDA
- Stock Information
- Founded
- ZTR 1988
- TRDA 2016
- Country
- ZTR Australia
- TRDA United States
- Employees
- ZTR N/A
- TRDA N/A
- Industry
- ZTR Investment Managers
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- TRDA Health Care
- Exchange
- ZTR Nasdaq
- TRDA Nasdaq
- Market Cap
- ZTR 338.8M
- TRDA 336.6M
- IPO Year
- ZTR N/A
- TRDA 2021
- Fundamental
- Price
- ZTR $6.17
- TRDA $7.60
- Analyst Decision
- ZTR
- TRDA Strong Buy
- Analyst Count
- ZTR 0
- TRDA 3
- Target Price
- ZTR N/A
- TRDA $25.67
- AVG Volume (30 Days)
- ZTR 219.4K
- TRDA 144.1K
- Earning Date
- ZTR 01-01-0001
- TRDA 05-08-2025
- Dividend Yield
- ZTR 12.09%
- TRDA N/A
- EPS Growth
- ZTR N/A
- TRDA N/A
- EPS
- ZTR N/A
- TRDA 0.61
- Revenue
- ZTR N/A
- TRDA $172,220,000.00
- Revenue This Year
- ZTR N/A
- TRDA N/A
- Revenue Next Year
- ZTR N/A
- TRDA N/A
- P/E Ratio
- ZTR N/A
- TRDA $12.53
- Revenue Growth
- ZTR N/A
- TRDA 5.74
- 52 Week Low
- ZTR $4.50
- TRDA $7.10
- 52 Week High
- ZTR $6.60
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- ZTR 60.53
- TRDA 39.41
- Support Level
- ZTR $6.06
- TRDA $7.42
- Resistance Level
- ZTR $6.23
- TRDA $8.05
- Average True Range (ATR)
- ZTR 0.09
- TRDA 0.40
- MACD
- ZTR -0.00
- TRDA -0.02
- Stochastic Oscillator
- ZTR 80.65
- TRDA 10.78
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.